NuVasive, Inc. (NASDAQ:NUVA) has earned a consensus recommendation of “Buy” from the nineteen analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and twelve have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $69.47.
NUVA has been the subject of several research analyst reports. Leerink Swann cut NuVasive from an “outperform” rating to a “market perform” rating in a report on Thursday, February 1st. Canaccord Genuity cut their price target on NuVasive from $81.00 to $73.00 and set a “buy” rating for the company in a report on Tuesday. Morgan Stanley cut their price target on NuVasive from $67.00 to $55.00 and set an “equal weight” rating for the company in a report on Tuesday. Piper Jaffray Companies restated a “buy” rating and set a $90.00 price target on shares of NuVasive in a report on Tuesday, January 9th. Finally, Wells Fargo & Co cut NuVasive from an “outperform” rating to a “market perform” rating and set a $65.00 price target for the company. in a report on Wednesday, January 17th.
Several institutional investors have recently made changes to their positions in the company. Westside Investment Management Inc. boosted its holdings in shares of NuVasive by 76.0% in the 4th quarter. Westside Investment Management Inc. now owns 2,640 shares of the medical device company’s stock worth $147,000 after purchasing an additional 1,140 shares during the period. Aperio Group LLC boosted its holdings in shares of NuVasive by 12.3% in the 4th quarter. Aperio Group LLC now owns 11,538 shares of the medical device company’s stock worth $675,000 after purchasing an additional 1,265 shares during the period. Meadow Creek Investment Management LLC lifted its stake in shares of NuVasive by 22.0% during the 4th quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the medical device company’s stock worth $429,000 after acquiring an additional 1,326 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of NuVasive by 6.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 22,927 shares of the medical device company’s stock worth $1,272,000 after acquiring an additional 1,452 shares during the last quarter. Finally, ING Groep NV lifted its stake in shares of NuVasive by 23.6% during the 4th quarter. ING Groep NV now owns 7,691 shares of the medical device company’s stock worth $450,000 after acquiring an additional 1,469 shares during the last quarter.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Monday, February 26th. The medical device company reported $0.56 earnings per share for the quarter, meeting the consensus estimate of $0.56. The business had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $272.11 million. NuVasive had a return on equity of 13.65% and a net margin of 6.36%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the business posted $0.53 EPS. equities analysts predict that NuVasive will post 1.91 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3226525/nuvasive-inc-nuva-given-average-rating-of-buy-by-brokerages.html.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.